Hematologic Malignancies

Suboptimal Use of Initial Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia

In a study of National Cancer Database data reported in Blood AdvancesVijaya Raj Bhatt, MD, of the University of Nebraska Medical Center, and colleagues found that...

Issues in Oncology
Palliative Care

Expanding the Use of Provider Orders for Life-Sustaining Treatment for Patients With Advanced Cancer

Patients with advanced cancer often get more aggressive treatment than they want because too few oncologists elicit their end-of-life treatment preferences...

Breast Cancer

Male Breast Cancer: An Understudied Malignancy

Male breast cancer is a rare and understudied malignancy when compared with female breast cancer, with conflicting literature on survival outcomes in men and women...


Lung Cancer

Active Surveillance of Lung Subsolid Nodules May Reduce Unnecessary Surgery and Overtreatment

Subsolid nodules can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance. Conservative management of subsolid nodules...


Issues in Oncology
Global Cancer Care

Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Barbados

Barbados is one of the Caribbean islands located in the Atlantic Ocean to the northeast of Venezuela. The island was uninhabited before the British established a settlement...


More Top Stories

Breast Cancer

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Results From the PAKT Trial

ASCO Answers Palliative Care: A Resource for Your Patients

THE ASCO ANSWERS Palliative Care booklet shares how palliative care or supportive care is used to manage symptoms and side effects; help with practical concerns; address spiritual questions; and support caregivers, family, and friends. Your patients will find: Practical advice on how to access ...


Sequential vs Concurrent Neoadjuvant Therapy in HER2-Positive Breast Cancer

As reported in JAMA Oncology by Buzdar et al, the phase III ACOSOG Z1041 (Alliance) trial showed no difference in disease-free or overall survival with sequential vs concurrent neoadjuvant anthracycline and trastuzumab in patients with operable HER2-positive breast cancer. An earlier report from...

Symptom Management

Susan Blumel, RN, BSN, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on Managing Toxicities of Immunotherapy

ASCO Volunteer Advocates Bringing Cancer Priorities to Capitol Hill for 2018 Advocacy Summit

ON SEPTEMBER 25–26, oncology care providers from across the United States will head to Capitol Hill to participate in the 3rd annual ASCO Advocacy Summit. Over 2 days, ASCO volunteer advocates will meet with members of Congress and their staff to educate them on critical issues affecting patients...


Clarifying the Complexity of Genomic Testing in Non-Hodgkin Lymphoma

AS MORE is learned about the genomic landscape in non-Hodgkin lymphoma, clinicians are grappling with how to apply this information in the clinic. At the 2018 Pan Pacific Lymphoma Conference, Andrew D. Zelenetz, MD, PhD, helped them understand this emerging area.1 Dr. Zelenetz is Professor of...

Origins and Genetics Associated With Mixed-Phenotype Acute Leukemia

Investigators have unraveled the origins and identified mutations associated with mixed-phenotype acute leukemia. The study, published by Alexander et al in Nature, potentially lays the foundation for more effective treatment of patients with this high-risk cancer. Mixed-phenotype acute...


Stephen M. Ansell, MD, PhD, on Hodgkin Lymphoma: Beyond Checkpoint Inhibitors

E. John Wherry, PhD, Named Chair of Systems Pharmacology at Perelman School of Medicine

E. John Wherry, PhD, has been appointed Chair of the Department of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine, University of Pennsylvania. Dr. Wherry is the Richard and Barbara Schiffrin President’s Distinguished Professor in the Department of...


Avelumab Plus Axitinib in Previously Untreated Patients With Advanced Kidney Cancer

The results of the pivotal phase III JAVELIN Renal 101 study—which evaluated avelumab (Bavencio) in combination with axitinib (Inlyta) compared with sunitinib (Sutent) as initial therapy for patients with advanced renal cell carcinoma—were recently announced. As part of a planned...

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.